p53 Monoclonal Antibody (SP5) | Invitrogen MA5-14516 product information

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

p53 Monoclonal Antibody (SP5)

catalog :

MA5-14516

quantity :

500 uL

price :

US 524.00

clonality :

monoclonal

host :

domestic rabbit

conjugate :

nonconjugated

clone name :

SP5

reactivity :

human, mouse, rat

application :

western blot, immunohistochemistry, immunocytochemistry, flow cytometry, immunohistochemistry - paraffin section

more info or order :

Invitrogen product webpage

citations: 28

Published Application/Species/Sample/Dilution	Reference
immunohistochemistry - paraffin section; human; 1:100; loading ...; tbl 1	Chung M, Lee J, Kim S, Suh Y, Choi H. Simple Prediction Model of Axillary Lymph Node Positivity After Analyzing Molecular and Clinical Factors in Early Breast Cancer. Medicine (Baltimore). 2016;95:e3689 pubmed publisher
immunohistochemistry; human; 1:200	Suryavanshi M, Mehta A, Jaipuria J, Sharma A, Rawal S, Seth N. Weaker ERG expression in patients with ERG-positive prostate cancer is associated with advanced disease and weaker androgen receptor expression: An Indian outlook. Urol Oncol. 2015;33:331.e9-15 pubmed publisher
immunohistochemistry; human; 1:200	Khandakar B, Mathur S, Kumar L, Kumar S, Datta Gupta S, Iyer V, et al. Tissue biomarkers in prognostication of serous ovarian cancer following neoadjuvant chemotherapy. Biomed Res Int. 2014;2014:401245 pubmed publisher
immunohistochemistry; human; 1:100	Staff S, Tolonen T, Laasanen S, Mecklin J, Isola J, Maenpaa J. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers. Int J Gynecol Pathol. 2014;33:309-16 pubmed publisher
immunohistochemistry; human	Ozer H, Yenicesu G, Arici S, Cetin M, Tuncer E, Cetin A. Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors. Diagn Pathol. 2012;7:124 pubmed publisher
immunohistochemistry; human; 1:1000	Meijer D, de Jong D, Pansuriya T, van den Akker B, Picci P, Szuhai K, et al. Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma. Genes Chromosomes Cancer. 2012;51:899-909 pubmed publisher
immunohistochemistry; human	Meijer Jorna L, van der Loos C, Teeling P, de Boer O, Florquin S, van der Horst C, et al. Proliferation and maturation of microvessels in arteriovenous malformations--expression patterns of angiogenic and cell cycle-dependent factors. J Cutan Pathol. 2012;39:610-20 pubmed publisher
immunohistochemistry; human; 1:50	Perisanidis C, Perisanidis B, Wrba F, Brandstetter A, El Gazzar S, Papadogeorgakis N, et al. Evaluation of immunohistochemical expression of p53, p21, p27, cyclin D1, and Ki67 in oral and oropharyngeal squamous cell carcinoma. J Oral Pathol Med. 2012;41:40-6 pubmed publisher
immunohistochemistry; human; 1:50	Schuster C, Berger A, Hoelzl M, Putz E, Frenzel A, Simma O, et al. The cooperating mutation or "second hit" determines the immunologic visibility toward MYC-induced murine lymphomas. Blood. 2011;118:4635-45 pubmed publisher
immunohistochemistry; human; 1:100	Lee D, Kim S, Suh Y, Kim S, Kim H, Shim B. Clinical implication of p53 overexpression in breast cancer patients younger than 50 years with a triple-negative subtype who undergo a modified radical mastectomy. Jpn J Clin Oncol. 2011;41:854-66 pubmed publisher
immunohistochemistry; human; 1:500	Sciuscio D, Diserens A, van Dommelen K, Martinet D, Jones G, Janzer R, et al. Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres. Clin Cancer Res. 2011;17:255-66 pubmed publisher
immunohistochemistry; human; 1:1	Abdelzaher E, El Gendi S, Yehya A, Gowil A. Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression. Br J Neurosurg. 2011;25:707-13 pubmed publisher
immunohistochemistry; human	Krishnamurti U, Zarineh A, Atem F, Silverman J. Correlation of immunohistochemical expression of p53 with unamplified chromosome 17 polysomy in invasive breast carcinoma. Appl Immunohistochem Mol Morphol. 2011;19:28-32 pubmed publisher
immunohistochemistry; human; 1:100	Myong N. Role of loss of o?-methylguanine dna methyltransferase (MGMT) expression in non-small cell lung carcinomas (NSCLCs): with reference to the relationship with p53 overexpression. Cancer Res Treat. 2010;42:95-100 pubmed publisher
immunohistochemistry; human	Bozkurt S, Ayan E, Bolukbasi F, Elmaci I, Pamir N, Sav A. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas. APMIS. 2009;117:651-9 pubmed publisher
immunohistochemistry; human; 1:40	Wang R, Wen M, Wang J, Ho S, Jan Y. Osteosarcoma arising in a long-standing uterine leiomyoma: a case report and literature review. Int J Surg Pathol. 2011;19:99-103 pubmed publisher
immunohistochemistry; rat	Arikan Y, Tosun M, Yilmaz S, Saykol V, Söylemez Z. The comparative effects of pneumoperitoneum on apoptosis and p53 expression in gastrointestinal organs. J Laparoendosc Adv Surg Tech A. 2008;18:365-71 pubmed publisher
immunohistochemistry; human; 1:25	Song Z, Wang Y, Xie L, Zang X, Yin H. Expression of senescence-related genes in human corneal endothelial cells. Mol Vis. 2008;14:161-70 pubmed
immunohistochemistry; human; 200 ug/ml	Aktas S, Kargi A, Olgun N, Diniz G, Erbay A, Vergin C. Prognostic significance of cell proliferation and apoptosis-regulating proteins in Epstein-Barr virus positive and negative pediatric Hodgkin lymphoma. Lymphat Res Biol. 2007;5:175-82 pubmed
immunohistochemistry; mouse	Navas T, Nguyen A, Hideshima T, Reddy M, Ma J, Haghnazari E, et al. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo. Leukemia. 2006;20:1017-27 pubmed
	Mart xed nez Iglesias O, Carrera I, Naidoo V, Cacabelos R. AntiGan: An Epinutraceutical Bioproduct with Antitumor Properties in Cultured Cell Lines. Life (Basel). 2022;12: pubmed publisher
	Wang Y, Li L, Zhang W, Zhang G. Circular RNA circLDB2 functions as a competing endogenous RNA to suppress development and promote cisplatin sensitivity in non-squamous non-small cell lung cancer. Thorac Cancer. 2021;12:1959-1972 pubmed publisher
	Xia W, Bai H, Deng Y, Yang Y. PLA2G16 is a mutant p53/KLF5 transcriptional target and promotes glycolysis of pancreatic cancer. J Cell Mol Med. 2020;24:12642-12655 pubmed publisher
	Lee K, Piett C, Andrews J, Mann E, Nagel Z, Gassman N. Defective base excision repair in the response to DNA damaging agents in triple negative breast cancer. PLoS ONE. 2019;14:e0223725 pubmed publisher
	Casadei L, Calore F, Braggio D, Zewdu A, Deshmukh A, Fadda P, et al. MDM2 Derived from Dedifferentiated Liposarcoma Extracellular Vesicles Induces MMP2 Production from Preadipocytes. Cancer Res. 2019;79:4911-4922 pubmed publisher
	Salmina K, Huna A, Inashkina I, Belyayev A, Krigerts J, Paštová L, et al. Nucleolar aggresomes mediate release of pericentric heterochromatin and nuclear destruction of genotoxically treated cancer cells. Nucleus. 2017;8:205-221 pubmed publisher
	Verreault M, Schmitt C, Goldwirt L, Pelton K, Haidar S, Levasseur C, et al. Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas. Clin Cancer Res. 2016;22:1185-96 pubmed publisher
	Lee D, Kim S, Kim S, Suh Y, Kim H, Shim B. Prognostic significance of breast cancer subtype and p53 overexpression in patients with locally advanced or high-risk breast cancer treated using upfront modified radical mastectomy with or without post-mastectomy radiation therapy. Int J Clin Oncol. 2012;17:447-55 pubmed publisher

product information

Product Type :

Antibody

Product Name :

p53 Monoclonal Antibody (SP5)

Catalog # :

MA5-14516

Quantity :

500 uL

Price :

US 524.00

Clonality :

Monoclonal

Purity :

protein A

Host :

Rabbit

Reactivity :

Human

Applications :

Flow Cytometry: 1:200, Immunocytochemistry: 1:100, Immunohistochemistry (Paraffin): 1:100, Western Blot: 1:10-1:500

Species :

Human

Clone :

SP5

Isotype :

IgG

Storage :

-20 C, Avoid Freeze/Thaw Cycles

Description :

The tumor suppressor protein, p53, is a sequence specific transcription factor that is activated by cellular stress. p53 mediates cell cycle arrest or apoptosis in response to DNA damage or starvation for pyrimidine nucleotides. p53 is up-regulated in response to stress signals and stimulated to activate transcription of specific genes, resulting in expression of p21waf1 and other proteins involved in G1 or G2/M arrest. The structure of p53 comprises an N-terminal transactivation domain, a central DNA-binding domain, an oligomerisation domain, and a C-terminal regulatory domain. There are various phosphorylation sites on p53, of which the phosphorylation at Ser15 is important for p53 activation and stabilization. p53 has been characterized to play a role in blocking the proliferative action of damaged cells and act as an anticancer agent. Phosphorylation of Ser392 in p53 has been shown to associate with the formation of human tumors. In addition, p53 has also been linked to the effects of aging and oxidative stress and an increase in p53 has been linked to deficits in LTP (Long Term Potentiation) in learning and memory. p53 is found in very low levels in normal cells, however, in a variety of transformed cell lines, it is expressed in high amounts, and believed to contribute to transformation and malignancy. Mutants of p53 that frequently occur in a number of different human cancers fail to bind the consensus DNA binding site, and cause the loss of tumor suppressor activity. Alterations of the TP53 gene occur not only as somatic mutations in human malignancies, but also as germline mutations in some cancer-prone families such as Li-Fraumeni syndrome.

Immunogen :

Recombinant human full-length wild type p53 protein

Format :

Liquid

Applications w/Dilutions :

Flow Cytometry: 1:200, Immunocytochemistry: 1:100, Immunohistochemistry (Paraffin): 1:100, Western Blot: 1:10-1:500

Aliases :

Antigen NY-CO-13; bbl; BCC7; bfy; bhy; cellular tumor antigen p53; Cys 51 Stop; EGK_08142; FLJ92943; HGNC11998; I79_002739; LFS1; Li-Fraumeni syndrome; mutant p53; mutant tumor protein 53; OTTMUSP00000006194; p44; p53; p53 cellular tumor antigen; p53 protein; p53 tumor suppressor; p53 tumor suppressor phosphoprotein; phosphoprotein p53; Tp53; tp53.L; transformation related protein 53; transformation-related protein 53; Trp248; Trp53; tumor protein 53; tumor protein p53; tumor protein p53 (Li-Fraumeni syndrome); tumor protein p53 L homeolog; tumor suppressor p53; tumor suppressor p53 phosphoprotein; tumor suppressor protein p53; tumor supressor p53; Tumour Protein p53; XELAEV_180196761mg; Xp53; Xrel3

more info or order :

Invitrogen product webpage